Zeiss has now released a video for marketing purposes which features CONVIVO as an integral component of their tumour workflow model. This involves a staged process from diagnosis through to treatment of cancers in the Central Nervous System. Zeiss has all the tools from KINEVO 900 through CONVIVO to radiotherapy. There were 296,851 tumours in the CNS identified in 2018.
https://www.zeiss.com/meditec/int/c/tumor-workflow-video.html
Zeiss are clearly serious in this field and are leading the world. OIL shareholders will be rewarded at some stage but timing is still hard to predict.
Zeiss marketing of Convivo
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $158.7M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 19.0¢ | $10.58K | 55.71K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31205 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 50018 | 2 |
View Market Depth
| Last trade - 15.59pm 23/08/2024 (20 minute delay) ? |
| OIL (ASX) Chart |